DDW Roundup

ImmusanT Inc., of Cambridge, Mass., presented Phase I data showing that Nexvax2 was well tolerated and induced a T-cell response confirming bioactivity in HLA-DQ2 genotype celiac disease patients. Nexvax2 is a therapeutic vaccine that combines three peptides that elicit an immune response in patients with the immune recognition gene HLA-DQ2. A Phase IIa trial is expected to begin within a year.